机构：[1]Department of Gastroenterology, PutuoPeople’s Hospital, Tongji UniversitySchool of Medicine, Shanghai 200060,People’s Republic of China[2]Departmentof Gastroenterology, Shanghai TenthPeople’s Hospital, Tongji UniversitySchool of Medicine, Shanghai 200072,People’s Republic of China[3]ShanghaiTongren Hospital, Shanghai JiaotongUniversity School of Medicine, Shanghai200336, People’s Republic of China
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. HCC incidence rate is sixth and mortality is fourth worldwide. However, HCC pathogenesis and molecular mechanisms remain unclear. The incidence of HCC is associated with genetic, environmental, and metabolic factors. The role of gut microbiota in the pathogenesis of HCC has attracted researchers' attention because of anatomical and functional interactions between liver and intestine. Studies have demonstrated the involvement of gut microbiota in the development of HCC and chronic liver diseases, such as alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and liver cirrhosis. Peroxisome proliferator-activated receptors (PPARs) are a group of receptors with diverse biological functions. Natural and synthetic PPAR agonists show potential for treatment of NAFLD, liver fibrosis, and HCC. Recent studies have demonstrated that PPARs take part in gut microbiota inhabitation and adaptation. This manuscript reviews the role of gut microbiota in the development of HCC and precancerous diseases, the role of PPARs in modulation of gut microbiota and HCC, and potential of gut microbiota for HCC diagnosis and treatment.
基金：
(1) National Natural Science
Foundation of China (No. 81670472); (2) the Yangfan Project
of Shanghai Science and Technology Commission (No.
20YF1443300); (3) the Natural Science Foundation of
Shanghai (No. 19ZR1447700); (4) the Health System
Innovation Project of Shanghai Putuo Science and
Technology Commission (No. PTKWWS201801, No.
PTKWWS201903); (5) WBN Hepatology Research Fund of
China Hepatitis Prevention and Treatment Foundation (No.
CFHPC2019031).
第一作者机构：[1]Department of Gastroenterology, PutuoPeople’s Hospital, Tongji UniversitySchool of Medicine, Shanghai 200060,People’s Republic of China[2]Departmentof Gastroenterology, Shanghai TenthPeople’s Hospital, Tongji UniversitySchool of Medicine, Shanghai 200072,People’s Republic of China
通讯作者：
通讯机构：[1]Department of Gastroenterology, PutuoPeople’s Hospital, Tongji UniversitySchool of Medicine, Shanghai 200060,People’s Republic of China[2]Departmentof Gastroenterology, Shanghai TenthPeople’s Hospital, Tongji UniversitySchool of Medicine, Shanghai 200072,People’s Republic of China[*1]Department of Gastroenterology, Putuo People’s Hospital, Tongji University School of Medicine, Shanghai 200060, People’s Republic of China
推荐引用方式(GB/T 7714)：
Yu Qiang,Wu Liwei,Ji Jie,et al.Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma[J].JOURNAL OF HEPATOCELLULAR CARCINOMA.2020,7:271-288.doi:10.2147/JHC.S277870.
APA：
Yu, Qiang,Wu, Liwei,Ji, Jie,Feng, Jiao,Dai, Weiqi...&Guo, Chuanyong.(2020).Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.JOURNAL OF HEPATOCELLULAR CARCINOMA,7,
MLA：
Yu, Qiang,et al."Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma".JOURNAL OF HEPATOCELLULAR CARCINOMA 7.(2020):271-288
